Plain-English translation of NCT07280013 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a combination of two medications— and —to see if they work well together and are safe for people with multiple myeloma that has come back or stopped responding to previous treatments. is taken as a tablet by mouth, while is given as an injection under the skin. The trial will first test different doses to find the safest level, then enroll more patients to confirm the results.
Multiple myeloma is a serious blood cancer, and many patients eventually develop resistance to standard treatments. Researchers believe this medication combination might offer a new option for people whose cancer has stopped responding to earlier therapies.
You likely qualify if…
You likely don't qualify if…
You would take tablets by mouth for 14 days, then have 14 days off each cycle (each cycle is 28 days long). You would also receive injections of under your skin twice each month. Additionally, you would receive a steroid medication (dexamethasone) by injection once a week for up to 4 cycles to help manage side effects. You would have regular clinic visits and blood tests to monitor how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States